IB409
/ Infensa Bioscience
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 29, 2026
A Phase 1, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of intravenously infused IB409 in healthy adult participants
(ANZCTR)
- P1 | N=48 | Completed | Sponsor: Infensa Bioscience Pyt Ltd | Recruiting ➔ Completed
Trial completion • Cardiovascular • Myocardial Infarction
November 15, 2025
A Phase 1, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of intravenously infused IB409 in healthy adult participants
(ANZCTR)
- P1 | N=48 | Recruiting | Sponsor: Infensa Bioscience Pyt Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2025
Enrollment open • Trial initiation date • Cardiovascular • Myocardial Infarction
1 to 2
Of
2
Go to page
1